Nearly two-thirds of adults ages 80 and older with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), two related types of…
News
NeuExcell Therapeutics‘ investigational gene therapy, NXL-004, showed a potential survival benefit in a small group of people with recurrent malignant glioma in an…
Cellxlife signed a licensing agreement for a cell-based vaccine from Mayo Clinic that aims to teach the body’s immune system to recognize and…
Tecvayli (teclistamab) extended survival and kept disease under control longer than standard treatments in patients with relapsed or refractory multiple myeloma, meaning the…
Adding iadademstat, an experimental blood cancer drug, to standard of care treatment for acute myeloid leukemia (AML) appeared to be safe and effective in…
Treatment with Revolution Medicines‘ oral daraxonrasib more than doubled overall survival versus standard chemotherapy among adults with previously treated metastatic pancreatic cancer in…
Preliminary Phase 1 trial data show that uTREAT, Curasight’s experimental targeted cancer therapy, was safely delivered to aggressive solid brain tumors and reached estimated…
SIM0505, a treatment being developed by Nextcure and Simcere Zaiming, resulted in partial responses in more than half of patients with hard- to-treat…
The European Commission has approved a new subcutaneous (under-the-skin) formulation of Sarclisa (isatuximab), a treatment for multiple myeloma that was previously available in…
The U.S. Food and Drug Administration (FDA) has approved a new formulation of the anticancer therapy nilotinib, branded Cavhanza, to treat certain people with chronic…
